rimegepant sulfate · Pfizer · NDA 212728
Nurtec Odt
Earliest generic entry, as listed
25 Mar 2039
Blocked by patent: US 11083724, US 11083724.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11083724 | product, use U-2718 | 25 Mar 2039 |
| US 11083724 | product, use U-3142 | 25 Mar 2039 |
| US 8314117 | substance, product, use U-2718 | 27 Feb 2034 |
| US 8314117 | substance, product, use U-3142 | 27 Feb 2034 |
| US 8759372 | substance, product | 25 Feb 2033 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic tentatively approved · 212728-00131 Dec 2025
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212728 · 001 · RLD | tablet, orally disintegrating, oral | EQ 75MG BASE | 25 Mar 2039 |